Autopsy report · NCT00727038

Lucentis for New Onset Neovascular Glaucoma

“Company withdrew funding/sponsorship”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

University of Illinois at Chicago

Sponsor type

University, hospital or other

Conditions

Glaucoma; New Onset Glaucoma; Neovascular Glaucoma; New Onset Neovascular Glaucoma

Interventions

Ranibizumab (Lucentis)

Participants

0

Trials that died the same way

• Ultrasound Image Fusion for Placement of Sacral Quadripolar Leads
  “Sponsor withdrew funding” (91% match in meaning)
• Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
  “Funding withdrawn by sponsor” (89% match in meaning)
• Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use
  “Lost funding from sponsor” (83% match in meaning)
• Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism
  “Withdrawal of sponsorship” (83% match in meaning)
• A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure
  “Sponsor lost funding” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.